3-chloro-5-(trifluoromethoxy)benzonitrile | 886503-29-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-chloro-5-(trifluoromethoxy)benzonitrile
• CAS: 886503-29-3
• 化学式: C₈H₃ClF₃NO
• mdl: MFCD06660309
• 分子量: 221.566
• InChiKey: RXIPYHUMXOYSSB-UHFFFAOYSA-N

物化性质

• 沸点：
  201.3±40.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  3-chloro-5-(trifluoromethoxy)benzonitrile 在 sodium hydrogen sulfide 、 一水合肼 、 magnesium chloride 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 5-[3-chloro-5-(trifluoromethoxy)phenyl]-1H-1,2,4-triazole
  参考文献：
  名称：

  [EN] NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF
  [FR] MODULATEURS DE TRANSPORT NUCLÉAIRE ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2011109799A8

文献信息

• NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
  申请人：Shacham Sharon

  公开号：US20110275607A1

  公开（公告）日：2011-11-10

  The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

  本发明通常涉及核运输调节剂领域，例如CRM1抑制剂，更具体地涉及新的取代杂环唑类化合物，这些化合物的合成和使用以及它们的制药组合物，例如在治疗、调节和/或预防与CRM1活性相关的生理状况方面的用途，例如治疗癌症和其他肿瘤性疾病、炎症性疾病、异常组织生长和纤维化疾病，包括心肌病、肺纤维化、肝纤维化、肾小球肾炎和其他肾脏疾病，以及治疗病毒感染（急性和慢性）。
• PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Alantos Pharmaceuticals, Inc.

  公开号：EP1910367A2

  公开（公告）日：2008-04-16
• HETEROBICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Alantos Pharmaceuticals, Inc.

  公开号：EP2038283A2

  公开（公告）日：2009-03-25
• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20060293345A1

  公开（公告）日：2006-12-28

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 inhibitors.
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.